Articles tagged with: Carfilzomib

News»

[ by and | Updated: Jun 4, 2013 1:41 pm | One Comment ]
ASCO 2013 Multiple Myeloma Update – Day Three: Poster Presentations

This year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago, began on Friday and goes through Tuesday.

Sunday started with a poster session in which important new research findings were summarized on posters displayed throughout a large conference hall.

The studies presented during the session were on a wide variety of myeloma-related topics, including new treatments being developed for myeloma, currently used regimens, smoldering multiple myeloma, and findings on initial therapy.

Some of the posters included preliminary results from ongoing clinical trials.  Others described …

Read the full story »

News»

[ by and | May 24, 2013 4:23 pm | 8 Comments ]
The Future Of Treatment For Multiple Myeloma

In a recent review article published in the journal Clinical Cancer Research, two myeloma experts from the Dana-Farber Cancer Institute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest strategies in the treatment of multiple myeloma.

In their article, the experts discuss newer therapies that appear to be promising in clinical and preclinical studies.

According to the physicians, combination therapies that specifically target a patient’s genetic form of the disease will be required for long-term disease control and ultimately a cure.

Some Historical Perspective

In their review article, Drs. …

Read the full story »

News»

[ by and | May 22, 2013 4:34 pm | Comments Off ]
Kyprolis Shows Good Response Rates In Heavily Pretreated High-Risk Myeloma Patients

A subanalysis of recent clinical trial results shows good response rates for single-agent Kyprolis in heavily pretreated multiple myeloma patients with high-risk chromosomal abnormalities.

Specifically, the investigators found that the response rates for patients with high-risk chromosomal abnormalities were similar to those for patients without high-risk chromosomal abnormalities.

However, the researchers also found that response duration and overall survival remained significantly lower in patients with high-risk chromo­som­al abnormalities.

Nevertheless, the researchers describe the results as encouraging, and they suggest that treatment with Kyprolis (carfilzomib) may be beneficial for patients …

Read the full story »

News»

[ by | May 20, 2013 2:42 pm | 3 Comments ]
Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2013)

The American Society of Clinical Oncology will hold its 49th annual meeting May 31 through June 4 in Chicago.

Similar to previous years, more than 25,000 clinical specialists from all over the world are expected to attend the five-day meeting to discuss the current research in cancer treatment and care. The theme for this year’s meeting is “Building Bridges to Conquer Cancer.”

During the meeting, there will be presentations and seminars about all areas of cancer, including many focused specifically on multiple myeloma. The ASCO website currently lists more than 

Read the full story »

Espanol»

[ by | Apr 19, 2013 6:51 pm | Comments Off ]
La combinación Kyprolis-Revlimid-dexametasona muestra resultados prometedores en mieloma indolente de alto riesgo (IMW 2013)

Los resultados iniciales de un ensayo clínico en marcha, en fase 2, muestran que Kyprolis en combinación con Revlimid y dexametasona a bajas dosis puede ser eficaz y seguro en pacientes con mieloma indolente de alto riesgo.

En concreto, los resultados muestran que todos los pacientes respondieron a la terapia combinada y que el 75 por ciento de ellos consiguieron por lo menos una remisión casi completa.

No se dispone todavía de cifras de progresión libre de enfermedad o de supervivencia global, por lo que aún no se sabe si …

Read the full story »